Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications, warning patterns

June 12, 2017 7:04am

Also an option expiration week (Friday, 16^th)

With a push-up and a down-pull aftermath

Pre-open indication: eight (8), 4 BUYS and 4 SELLS

Critical indications ahead of “our” universe’s open! I provide intelligence and analysis for short-term investment.

Are you a subscriber? If not – you’re missing the realities of “our” universe?

I know what a company is supposed to look like, be like, and smell like to succeed!

A lower open expected

Dow futures are DOWN -0.15% and NASDAQ futures are down -0.65%

U.S. stock index futures pointed to a lower open on Monday morning as traders responded to the latest political elections in Europe and looked ahead to the Federal Reserve's latest meeting later this week.

European markets were lower as investors took a cautious approach as they came to terms with a hung parliament in the U.K. and awaited a meeting of the Federal Reserve later this week.

Asian markets traded lower as tech stocks plunged, mirroring the fall in tech names stateside. Markets in Australia, Malaysia and the Philippines were closed today for public holidays.

Data docket: will see the latest federal budget announcement. There are no significant earnings expected on Monday.

The cell therapy sector closed NEGATIVE on Friday, POSITIVE on Thursday and NEGATIVE on Wednesday, Tuesday and last Monday. The cell therapy sector’s record over the last 5 days (of 43 covered companies):

· Friday closed NEGATIVE with 29 decliners, 13 advancers and 1 flat;

· Thursday closed POSITIVE with 12 decliners, 30 advancers and 1 flat;

· Wednesday closed NEGATIVE with 21 decliners, 16 advancers and 6 flats;

· Tuesday closed NEGATIVE with 19 decliners, 18 advancers and 6 flats;

· Last Monday closed NEGATIVE with 30 decliners, 10 advancers and 3 flats;

Remembering Friday’s closing bell newsletter, “it was time to make a deposit … … From the “sells” into strength.”

Reiterating, “As I had stated, “There are dollars on the table and trader’s daggers are out for profit-taking”. The upsides are trending toward being overbought.”

What did I see on Friday, the DOW closed UP+0.42% (+89.44) as the NASDAQ closed DOWN -1.80% (-113.85) … while the CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10.6 after … Thursday’s 10.2.

Volatility has dropped to a 23-year low with the (.VIX) falling below the psychologically key 10 level.

However, I more than speculate that the selloff is the start of something more ominous in a cell therapy sector.

Traders will be cover ing… pumping some share pricing for a bigger sell-off!

investors are re-evaluating valuations – they are TOO far from the present value.

And … the end of Q2 is approaching; what real news has materialized in the “papers”

Cash positions and operating costs will be on display … to be measured against developments!

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?

Watch list:

The iShares Nasdaq Biotechnology (IBB) closed down -0.22% on Friday, and indicates a POSITIVE +0.04% in Monday’s pre-market;
The SPDR S&P Biotech ETF (XBI) closed Friday down -0.38%, was down -0.12% in the afterhours and is NOT indicating in Monday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) closed up +0.68% Friday, and is NOT indicating in Monday’s pre-open;
The iShares Russell 2000 (IWM) closed up +0.52% on Friday, and indicating a NEGATIVE -0.25% in Monday’s pre-open

Companies in my headlights:

…………..Investors are nervous; traders are fickle after markets see-sawed last Friday ………

Applied Genetic Technologies (AGTC) closed up +$0.25 to $5.25 following Thursday’s $5.00 (+$0.15) after Wednesday’s flat at $4.85. The aftermarket indication is a negative -$0.25 or -4.76% – BUY to SELL;

Bellicum Pharmaceuticals (BLCM) closed down -$0.40 to $10.24. June started at $10.93 with a high of $10.99 and a low of $10.24. The aftermarket indication is a positive +$0.05 or +0.49% - BUY;

bluebird bio (BLUE) closed up +$0.90 to $111.90 after Thursday’s $111.00 (+$1.85) after Wednesday’s $109.15 (+$10.95) following Tuesday’s $98.20 (+$6.90) after Monday’s $81.30 (+$7.15) after last Friday’s $85.15 (+$4.95). There is a week’s worth of upside -$21.75, time to exit (-19.4%) to come back again. The pre-market indication is a negative -$0.05 or -0.04% – Maintaining SELL;

Juno Therapeutics (JUNO) closed down -$0.68 to $21.68 following Thursday’s $22.36 (-$1.37) after Wednesday’s $23.73 (-$0.47) following Tuesday’s $24.20 (+$0.81) after last Monday’s $23.40 (-$2.81) following the previous Friday’s $26.21 (+$1.71). The aftermarket indication is a positive +$0.16 or +0.74% - Maintaining BUY;

Kite Therapeutics (KITE) closed up +$1.12 to $87.79 following Thursday’s $86.67 (+$4.57) after Wednesday’s $82.10 (+$5.46) following Tuesday’s $76.64 (+$3.03) after Monday’s $73.61 (-$1.88) following Friday’s $75.49 (+$0.83). There is $13.13 or 15% of upside ready to be taken – Maintaining SELL;

Spark Therapeutics (ONCE) closed down -$0.48 to $53.93. June started at $52.18 with a high of $54.74 and a low of $51.60 - so far. The aftermarket indication is a positive +$0.15 or +0.28% - BUY;

Sangamo (SGMO) closed down -$0.35 to $7.30 following Thursday’s $7.65 (+$0.40). June has been a good month as the stock started at $7.00 and has steadily appreciated; I’d be selling as May started at $4.85 ended at $6.80 with a high of $8.40 and a low of $4.35. The aftermarket indication is a negative -$0.20 or -2.74% – Maintaining SELL;

Verastem (VSTM) closed down -$0.07 to $21.3 following Thursday’s $2.20 (+$0.08) following Wednesday’s $2.12 (-$0.09) after Tuesday’s $2.17 (+$0.02), Monday’s $2.15 (-$0.04) last Friday’s $2.19 (+$0.01). The aftermarket indication is a positive +$0.015 or +0.71% - Maintaining BUY;

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.